In the preceding three months, 16 analysts have released ratings for Blueprint Medicines (NASDAQ:BPMC), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 7 | 5 | 3 | 0 | 1 |
Last 30D | 0 | 1 | 0 | 0 | 0 |
1M Ago | 0 | 1 | 0 | 0 | 0 |
2M Ago | 7 | 3 | 3 | 0 | 1 |
3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $115.5, a high estimate of $168.00, and a low estimate of $75.00. Marking an increase of 19.69%, the current average surpasses the previous average price target of $96.50.
Analyzing Analyst Ratings: A Detailed Breakdown
A comprehensive examination of how financial experts perceive Blueprint Medicines is...
Login or create a forever free account to read this news
Sign up/Log in